BCL2 and neoplasm: However, currently known senescence scavengers, such as MDM2 inhibitors and BCL-2 family inhibitors, are not cell specific, and, therefore, the removal of senescent anti-tumor immune cells will lead to unpredictable toxic side effects (34, 35).